Tech Company Financing Transactions
Thesan Pharmaceuticals Funding Round
Thesan Pharmaceuticals, based in Carlsbad, secured $16 million in funding from Novartis Venture Fund and Novo Ventures.
Transaction Overview
Company Name
Announced On
11/1/2012
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series A
Investors
Novartis Venture Fund (Lead Investor) (Giovanni Ferrara)
Novo Ventures (Lead Investor) (Peter Bisgaard)
Proceeds Purpose
The company will focus on the development of novel approaches for the treatment of dermatological disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5864 Owens Ave. 200
Carlsbad, CA 92008
USA
Carlsbad, CA 92008
USA
Phone
Undisclosed
Website
Email Address
Overview
Thesan Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to the development of novel therapeutics for disorders of the skin. Thesan is focused on the discovery and development of New Chemical Entities that have the potential to provide significantly improved treatment options to patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bernard King
Chief Financial Officer
Leslie Schulze
Chief Medical Officer
Howard Welgus
Executive Vice President
George Mooney
VP - Product Management
Jay Birnbaum
VP - Regulatory Affairs
Charlotte Merritt
Browse more venture capital transactions:
Prev: 10/31/2012: Reflexion Health venture capital transaction
Next: 11/1/2012: Syntellia venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs